Scientists reveal new TEV-mediated αPD-L1-specific therapy resistance mechanism
The immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 antibodies (αPD-1 and αPD-L1), have revolutionized tumor immunotherapy. Although αPD-1 and αPD-L1 show excellent efficacy in various tumor types, even ...
Oct 31, 2022
0
2